The Looming US Election Weighs On The Minds Of Pharma

The US presidential election in November could mean IRA expansion from a Biden win, but a Trump victory also brings uncertainty.

Pharma is keeping a close eye on the 2024 election • Source: Shutterstock

The outcome of the US presidential election in November, whether Democrat president Joe Biden wins the election or former Republican president Donald Trump, is bound to result in continued emphasis on drug prices and health care spending.

Key Takeaways

  • Whether Democrats retain power in the White House or Republicans step back into the oval office, drug pricing is expected to remain a political pressure point.

Pharmaceutical executives and industry experts discussed implications of the upcoming election for pharma during the Financial Times US Pharma &...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip